Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels

Published:2019-11-01 Issue:11 Volume:4 Page:1067
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Ray Kausik K.¹,Stoekenbroek Robert M.²,Kallend David²,Nishikido Toshiyuki³,Leiter Lawrence A.⁴,Landmesser Ulf⁵,Wright R. Scott⁶,Wijngaard Peter L. J.²,Kastelein John J. P.⁷

Affiliation:

1. Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, Charing Cross Hospital, London, England

2. The Medicines Company, Parsippany, New Jersey

3. Cardiovascular Medicine, Saga University, Nabeshima, Saga, Japan

4. University of Toronto, Toronto, Ontario, Canada

5. Charité-Universitats medizin Berlin, Berlin, Germany

6. Department of Cardiology, Mayo Clinic, Rochester, Minnesota

7. University of Amsterdam, Amsterdam, the Netherlands

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2751334/jamacardiology_ray_2019_oi_190059.pdf

Reference16 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease, 1. evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel.;Ference;Eur Heart J,2017

2. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease.;Navar-Boggan;Circulation,2015

3. Evolocumab and clinical outcomes in patients with cardiovascular disease.;Sabatine;N Engl J Med,2017

4. Alirocumab and cardiovascular outcomes after acute coronary syndrome.;Schwartz;N Engl J Med,2018

5. Impact of lipids on cardiovascular health: JACC health promotion series.;Ference;J Am Coll Cardiol,2018

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database;International Journal of Clinical Pharmacy;2024-08-27

2. RNA interference therapy in cardiology: will new targets improve therapeutic goals?;Drugs in Context;2024-08-20

3. Nucleic Acid Armor: Fortifying RNA Therapeutics through Delivery and Targeting Innovations for Immunotherapy;International Journal of Molecular Sciences;2024-08-15

4. Lipidmanagement bei Typ-2-Diabetes mellitus – Strategien zur Risikoreduktion;Aktuelle Kardiologie;2024-07-31

5. Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations;Frontiers in Pharmacology;2024-07-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3